Baker McKenzie Switzerland played a pivotal role in advising Mateco group on its acquisition of Maltech Holding and subsidiaries, the prominent Swiss market leader in rentable lifting platforms. This acquisition marks a significant stride in
Tags :Slider
Baker McKenzie Switzerland played a pivotal role in advising Lalique Group on the acquisition of a substantial 75% stake in the renowned wine estate, Château Lafaurie-Peyraguey, for a notable EUR 18 million. This strategic move not
In a strategic move to advance innovation in the Infection Control and Life Science domain, Metall Zug and Miele have inked a transformative agreement. The deal outlines the creation of a new joint venture, where
In a strategic move, Ringier has successfully acquired all shares in the former Swiss joint venture, Ringier Axel Springer Schweiz (RASCH), from Axel Springer. The joint venture, established in 2016, has been a collaborative effort until
Kohlberg Kravis Roberts (KKR) makes a significant investment into the Precipart Group, a renowned contract manufacturer of high-precision components to the medical, aerospace and industrial markets. KKR plans to support the company in its continued
In a resounding success, Lonza has secured its financial future by placing two tranches totaling CHF 400 million. The first tranche of CHF 185 million, featuring a 2.25% interest rate and maturing in 2028, was complemented by a second
Baker McKenzie, with its teams in Singapore, Switzerland, and Japan, served as legal advisor to DBS Bank, UBS, and SBI Digital Asset Holdings in executing the world’s first cross-border repo and natively-issued digital bond
Homburger provided legal counsel to Commerzbank Aktiengesellschaft for a syndicated corporate financing deal involving Montana Aerospace. This company is a well-known manufacturer of aerospace system components and complex assemblies, operating globally with development and production
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate
Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) has acquired the 68.0% of the shares in Swiss pharmaceutical company Osmopharm and has disinvested the 76.4% in Egyptian pharmaceutical manufacturer SPIMACO Misr for Pharmaceutical Industries. The Transaction, with
